newsfilter
← Latest News
GlobeNewswire·

Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of IVX-A12; topline